PubMed (MeSH Keyword) for id: 71236992

Year	Number of Results
2018	3
2019	3
2020	6
2021	4
2022	2
2023	2
2024	0

1

Hepatocyte CD36 protects mice from NASH diet-induced liver injury and fibrosis via blocking N1ICD production.

Li Y, Zhang L, Jiao J, Ding Q, Li Y, Zhao Z, Luo J, Chen Y, Ruan X, Zhao L. Li Y, et al. Biochim Biophys Acta Mol Basis Dis. 2023 Oct;1869(7):166800. doi: 10.1016/j.bbadis.2023.166800. Epub 2023 Jul 7. Biochim Biophys Acta Mol Basis Dis. 2023. PMID: 37423141

2

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.

García-Guerrero E, Rodríguez-Lobato LG, Sierro-Martínez B, Danhof S, Bates S, Frenz S, Haertle L, Götz R, Sauer M, Rasche L, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M, Prommersberger SR. García-Guerrero E, et al. Haematologica. 2023 Feb 1;108(2):568-580. doi: 10.3324/haematol.2022.281339. Haematologica. 2023. PMID: 36722406 Free PMC article.

3

Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.

Mancarella S, Gigante I, Serino G, Pizzuto E, Dituri F, Valentini MF, Wang J, Chen X, Armentano R, Calvisi DF, Giannelli G. Mancarella S, et al. J Exp Clin Cancer Res. 2022 Nov 28;41(1):331. doi: 10.1186/s13046-022-02536-6. J Exp Clin Cancer Res. 2022. PMID: 36443822 Free PMC article.

4

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.

Massard C, Cassier PA, Azaro A, Anderson B, Yuen E, Yu D, Oakley G 3rd, Benhadji KA, Pant S. Massard C, et al. Cancer Chemother Pharmacol. 2022 Oct;90(4):335-344. doi: 10.1007/s00280-022-04461-z. Epub 2022 Aug 28. Cancer Chemother Pharmacol. 2022. PMID: 36030462 Clinical Trial.

5

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.

Azaro A, Massard C, Tap WD, Cassier PA, Merchan J, Italiano A, Anderson B, Yuen E, Yu D, Oakley G 3rd, Benhadji KA, Pant S. Azaro A, et al. Invest New Drugs. 2021 Aug;39(4):1089-1098. doi: 10.1007/s10637-021-01094-6. Epub 2021 Mar 8. Invest New Drugs. 2021. PMID: 33686452 Clinical Trial.

6

Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.

Borthakur G, Martinelli G, Raffoux E, Chevallier P, Chromik J, Lithio A, Smith CL, Yuen E, Oakley GJ 3rd, Benhadji KA, DeAngelo DJ. Borthakur G, et al. Cancer. 2021 Feb 1;127(3):372-380. doi: 10.1002/cncr.33188. Epub 2020 Oct 27. Cancer. 2021. PMID: 33107983 Free article. Clinical Trial.

7

Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients.

Mir O, Watson S, Massard C, Le Cesne A, Benhadji KA, Soria JC. Mir O, et al. Ann Oncol. 2020 Dec;31(12):1782-1784. doi: 10.1016/j.annonc.2020.09.003. Epub 2020 Sep 14. Ann Oncol. 2020. PMID: 32941988 Free article. No abstract available.

8

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.

Doi T, Tajimi M, Mori J, Asou H, Inoue K, Benhadji KA, Naito Y. Doi T, et al. Invest New Drugs. 2021 Apr;39(2):469-476. doi: 10.1007/s10637-020-01001-5. Epub 2020 Sep 16. Invest New Drugs. 2021. PMID: 32939607 Free PMC article. Clinical Trial.

9

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.

Azaro A, Baldini C, Rodon J, Soria JC, Yuen E, Lithio A, Oakley G, Benhadji KA, Massard C. Azaro A, et al. Invest New Drugs. 2021 Feb;39(1):193-201. doi: 10.1007/s10637-020-00944-z. Epub 2020 Sep 11. Invest New Drugs. 2021. PMID: 32915419 Clinical Trial.

10

Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.

Mancarella S, Serino G, Dituri F, Cigliano A, Ribback S, Wang J, Chen X, Calvisi DF, Giannelli G. Mancarella S, et al. Cell Death Differ. 2020 Aug;27(8):2330-2343. doi: 10.1038/s41418-020-0505-4. Epub 2020 Feb 10. Cell Death Differ. 2020. PMID: 32042099 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

15 results

Results by year